Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dihydroergocristine→

Dihydroergocristine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
17479-19-5
Molecular formula
C35H41N5O5
Molecular weight
611.7 g/mol
Drug class
Ergot alkaloidpartial agonist/antagonist at adrenergic, serotonergic and dopaminergic receptors
Mechanism of action
Interacts with alpha-adrenergic, serotonergic and dopaminergic receptors. The mechanism underlying historical cognitive or vascular indications is not firmly established and may vary by preparation.
Indications / reported uses
  • Historical or regional use in fixed ergot-alkaloid mixtures for selected vascular or cognitive symptoms; it is not an established evidence-based treatment for postpartum haemorrhage. Do not carry over that indication from RxClass.

Sources: NLM MeSH — Dihydroergocristine · PubMed — Dihydroergocristine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dihydroergocristine Environmental Risk Assessment (ERA) (the Dihydroergocristine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.